The estimated Net Worth of Paul Bisaro is at least $28.5 million dollars as of 10 February 2024. Mr. Bisaro owns over 1,463 units of Zoetis Inc stock worth over $4,138,362 and over the last 12 years he sold ZTS stock worth over $24,032,600. In addition, he makes $355,000 as Independent Director at Zoetis Inc.
Sign up
Mr. Bisaro ZTS stock SEC Form 4 insiders trading
Paul has made over 16 trades of the Zoetis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,463 units of ZTS stock worth $277,955 on 10 February 2024.
The largest trade he's ever made was exercising 527,200 units of Zoetis Inc stock on 7 August 2013 worth over $16,163,952. On average, Paul trades about 12,982 units every 56 days since 2013. As of 10 February 2024 he still owns at least 21,782 units of Zoetis Inc stock.
You can see the complete history of Mr. Bisaro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Bisaro biography
Paul M. Bisaro is Independent Director of the Company. Mr. Bisaro formerly served as President and Chief Executive Officer from March 2017 to May 2018. Mr. Bisaro was previously the Executive Chairman of the board of directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals). He was appointed President, Chief Executive Officer and a member of the board of Watson in September 2007 and was later appointed Board Chairman in October 2013. Prior to Watson, Mr. Bisaro was President, Chief Operating Officer and member of the board of Barr Pharmaceuticals, Inc. Mr. Bisaro served as Barr’s General Counsel from 1992 to 1999, and from 1997 to 1999 served in various additional capacities including Senior Vice President – Strategic Business Development. Prior to Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the Board of TherapeuticsMD, Inc., a women’s health pharmaceutical company, and on the Board of Visitors of The Catholic University of America’s Columbus School of Law. Mr. Bisaro previously served on the boards of Allergan plc from 2007 to 2018, Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, from 2013 to 2017 and Amneal Pharmaceuticals (and its predecessor Impax) from March 2017 to August 2019. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaro’s business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of our Board.
What is the salary of Paul Bisaro?
As the Independent Director of Zoetis Inc, the total compensation of Paul Bisaro at Zoetis Inc is $355,000. There are 8 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.
How old is Paul Bisaro?
Paul Bisaro is 59, he's been the Independent Director of Zoetis Inc since 2015. There are 9 older and 13 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.
What's Paul Bisaro's mailing address?
Paul's mailing address filed with the SEC is 322 NORTH 2200 WEST, , SALT LAKE CITY, UT, 84116.
Insiders trading at Zoetis Inc
Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio et Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.
What does Zoetis Inc do?
Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
What does Zoetis Inc's logo look like?
Complete history of Mr. Bisaro stock trades at Myriad Genetics, Mallinckrodt Plc, Zimmer Biomet Inc, Zoetis Inc, TherapeuticsMD, Enact Inc et Amneal Pharmaceuticals Inc
Zoetis Inc executives and stock owners
Zoetis Inc executives and other stock owners filed with the SEC include:
-
Glenn David,
Chief Financial Officer, Executive Vice President -
Kristin Peck,
Chief Executive Officer, Director -
Catherine Knupp,
Executive Vice President, President - Research and Development -
Kristin C. Peck,
CEO & Director -
Wafaa Mamilli,
Exec. VP and Chief Information & Digital Officer -
Roman Trawicki,
Exec. VP and Pres of Global Manufacturing & Supply -
Glenn C. David,
Exec. VP and Group Pres of International Operations, Aquaculture, BioDevices & Pet Insurance -
Michael McCallister,
Non-Executive Independent Chairman of the Board -
Robert Scully,
Independent Director -
Gregory Norden,
Independent Director -
Paul Bisaro,
Independent Director -
William Steere,
Independent Director -
Linda Rhodes,
Independent Director -
Willie Reed,
Independent Director -
Louise Parent,
Independent Director -
Sanjay Khosla,
Independent Director -
Frank D'Amelio,
Independent Director -
Roman Trawicki,
Executive Vice President, President - Global Manufacturing and Supply -
Heidi Chen,
Executive Vice President, General Counsel, Corporate Secretary -
Roxanne Lagano,
Chief Human Resource Officer, Executive Vice President and Global Operations -
Heidi C. Chen,
Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics -
Roxanne Lagano,
Exec. VP and Chief HR Officer & Global Operations -
Wetteny N. Joseph,
Exec. VP & CFO -
Timothy J. Bettington,
Exec. VP and Pres of U.S. Operations & Global Customer Experience -
William Price,
VP & Chief Communications Officer -
Steven Frank,
VP of Investor Relations -
Gavin Hattersley,
Director -
Robert Edward Kelly,
Executive Vice President -
Alejandro Bernal,
Executive Vice President -
Juan Ramon Alaix,
Director -
Clinton A. Jr. Lewis,
Executive Vice President -
Sherry N Pudloski,
Executive Vice President -
Robert J Polzer,
Executive Vice President -
Amy W Schulman,
Director -
Sandra J. Beaty,
Executive Vice President -
Joyce J. Lee,
Executive Vice President -
Douglas E. Giordano,
Director -
William F Doyle,
-
Inc Pfizer,
Director -
Square Capital Management, ...,
-
Stefan Weiskopf,
Executive Vice President -
Richard A. Passov,
EVP, Chief Financial Officer -
Paul Herendeen,
Exec. V.P. and CFO -
Charles H Hill,
Director -
Geno J Germano,
Director -
Andrew Fenton,
Executive Vice President -
James Michael Mc Farland,
Executive Vice President -
Wafaa Mamilli,
Executive Vice President -
Timothy J Bettington,
Executive Vice President -
Antoinette Renee Leatherberry,
Director -
Astorga Jeannette Ferran,
Executive Vice President -
Abhay U Nayak,
Executive Vice President -
Wetteny Joseph,
Chief Financial Officer -
Rimma Driscoll,
Executive Vice President -
Vanessa Broadhurst,
Director -
Jamie Brannan,
Executive Vice President -
Nicholas Ashton,
Executive Vice President -
Soria Ester Banque,
Executive Vice President